GxP Computer System Validation Plan Generator

This agent transforms weeks of validation planning into minutes by generating complete, GxP-compliant Computer System Assessment (CSA) validation plans. Built by a 25-year pharmaceutical validation expert using current FDA CSA Guidance (2026), GAMP5 2nd Edition, and 21 CFR Part 11 requirements, it delivers ready-to-use documentation for new implementations, revalidations, and periodic reviews. Perfect for validation leads, QA engineers, pharmaceutical quality managers, biotech compliance teams, and medical device quality professionals who need regulatory-compliant validation plans without the traditional time investment. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SAMPLE OUTPUT — MasterControl QMS Validation Plan (truncated for display — full output is 2,400+ words) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ DOCUMENT CONTROL HEADER Document Number: VP-MQMS-2026-001 | Version: 0.1 | Status: DRAFT System: MasterControl QMS | Vendor: MasterControl Inc. | Version: 2024.1 Validation Type: New Implementation | GxP Impact: HIGH SECTION 2: PURPOSE This Validation Plan establishes the strategy, scope, deliverables, roles, and acceptance criteria governing the CSA activities for MasterControl QMS at the Pharmaceutical Manufacturing Facility. This effort is conducted in accordance with the FDA CSA Guidance (February 2026) and GAMP5 Second Edition (2022), applying a risk-proportionate approach calibrated to the system's HIGH GxP impact classification. Validation is required because MasterControl QMS will create, manage, and archive electronic records that directly support GMP-regulated pharmaceutical manufacturing operations — including document control, CAPA management, change control, deviation management, supplier qualification, and training records — all subject to FDA predicate rules and data integrity requirements. SECTION 6: REGULATORY BASIS (excerpt) ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Regulation | Applicability ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ FDA CSA Guidance (February 2026) | Primary validation framework GAMP5 2nd Edition (2022) | Category 4 classification + testing 21 CFR Part 11 | SUBJECT — e-records + e-signatures 21 CFR Parts 210/211 | GMP predicate rules ICH Q9(R1) (2023) | Risk management methodology EU Annex 11 (2011) | EU-regulated site requirements MHRA Data Integrity Guidance (2018) | ALCOA+ principles ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ SECTION 10: 21 CFR PART 11 ASSESSMENT (excerpt) Determination: SUBJECT TO 21 CFR PART 11 Applicable requirements verified (all 11.10 sub-requirements): 21 CFR 11.10(a) — System Validation 21 CFR 11.10(b) — Accurate and Complete Copies 21 CFR 11.10(c) — Record Protection 21 CFR 11.10(d) — Access Controls 21 CFR 11.10(e) — Audit Trails 21 CFR 11.10(f) — Operational Checks 21 CFR 11.10(g) — Authority Checks 21 CFR 11.10(h) — Device Checks 21 CFR 11.10(i) — Personnel Qualifications 21 CFR 11.10(j) — Written Policies and Procedures 21 CFR 11.10(k) — Electronic Signature Controls [Full document includes: GAMP5 Category rationale, Risk Summary Table, V-Model Lifecycle, RACI Matrix, 13 Validation Deliverables with Document IDs, IQ/OQ/PQ Testing Strategy, Data Migration Plan, Acceptance Criteria, References, and Approval Signature Block] DRAFT — Generated by QualGen AI CSA Validation Plan Generator v2.0 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━